Key information

🔎 Fund Overview

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity. Its product pipeline includes TERN-701, TERN-501, TERN-601 and TERN-101. ItsTERN-701 is an oral, potent, allosteric BCR-ABL tyrosine kinase inhibitor (TKI) specifically targeting the ABL myristoyl pocket for chronic myeloid leukemia. The TERN-501 is its highly selective thyroid hormone receptor beta (THR-b) agonist for non-alcoholic steatohepatitis (NASH) in Phase IIa clinical development. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist for metabolic diseases such as obesity. TERN-101 is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR), agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver.